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The rapid evolution in personalized medicine for patients with advanced non— small-cell lung cancer (NSCLC) has brought considerable benefits for those whose tumors 
are addicted to a particular ongogenic driver, but posed new challenges for pathologists 
in identifying those cases. Epidermal growth factor receptor (EGFR) mutation testing, to 
underpin the prescription of EGFR tyrosine kinase inhibitors (TKIs), is now a standard of 
care, where a range of methods may be used to detect and identify the mutation, subject to 
appropriate validation.1
The anaplastic lymphoma kinase (ALK) TKIs are the second class of  biomarker-selected 
“molecularly targeted” treatments to reach maturity in NSCLC therapy, for patients whose 
tumors harbor an ALK gene rearrangement.2–4 The laboratory identification of ALK gene 
rearrangements has, however, been a rather more contentious issue. These rearrangements 
are relatively heterogeneous; at least 27 variants have now been described, the vast majority 
in patients with adenocarcinoma.5 Most involve an inversion in chromosome 2p, placing 
a variable length of the echinoderm microtubule-associated protein-like 4 (EML4) gene 
and its promoter upstream of the ALK tyrosine kinase domain. Other fusion partners from 
other chromosomes have the same effect—overexpression of a constitutively activated 
ALK tyrosine kinase with pro-oncogenic effects. Crizotinib was the “first in class” ALK 
TKI approved by the U.S. Federal Drug Administration (FDA), in conjunction with a spe-
cific companion diagnostic, the Vysis LSI ALK Dual Colour, Break-Apart Rearrangement 
Probe (Abbott Molecular, Abbott Park, IL). This was the methodology used in the trials that 
led to the approval of crizotinib; thus, the ALK fluorescence in situ hybridization (FISH) 
test became the “standard procedure” for patient identification.
FISH testing, and ALK FISH testing in NSCLC in particular, is generally acknowl-
edged as being relatively costly, time-consuming, requires specialized equipment, and 
requires considerable expertise.6 Inversions in 2p in particular lead to relatively small phys-
ical separation of the two ALK fragments, sometimes making the “break apart” difficult to 
identify. In addition, the requirement for 50 assessable cells to be read, of which at least 
15% should show rearrangement for a “positive test,” means that as many as 20% of routine 
diagnostic lung cancer samples requiring testing fall short of this requirement.6 Although 
not “FDA approved,” alternative methods for detecting ALK fusions are attractive.
Reverse-transcriptase polymerase chain reaction (RT-PCR) was the method origi-
nally used to identify the EML4-ALK gene rearrangement in NSCLC.7 It is a highly sensi-
tive and specific technique, but it has drawbacks. The ever-increasing number of fusion 
partners for the ALK gene mandates a multiplex RT-PCR approach with multiple specific 
primers, a relatively “specialist” technique. A greater problem, however, is the availability 
of adequate quality messenger RNA from tumor samples. Most published studies used 
fresh-frozen tumor samples. Formalin-fixed, paraffin-embedded samples generally are a 
poor, unreliable source of messenger RNA. Unfixed cytology type samples have been used 
in some specialized centers but questions arise over the presence of tumor cells in unex-
amined test samples, and this approach also poses logistical issues. RT-PCR is not recom-
mended in the College of American Pathologists/International Association for the Study of 
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Lung Cancer/Association for Molecular Pathology guidelines 
on ALK testing.1
ALK gene rearrangement in NSCLC is associated with 
a modest elevation in cytoplasmic Alk protein, which may be 
detected by immunohistochemistry (IHC). Pathologists have 
long used standard IHC approaches to detect the substantial 
protein elevations in ALK-rearranged anaplastic lymphoma, 
after which the gene is named. These same techniques were 
found wanting in NSCLC, through low primary antibody 
sensitivity but, more importantly, insufficiently sensitive IHC 
detection systems.8 The ALK1 antibody clone (Dako, Glostrup, 
Denmark) fell short in some studies, but many subsequent 
publications, using either the D5F3 clone (Cell Signalling 
Technologies,  Ventana-Roche, Tucson, AZ) or the 5A4 clone 
(Leica-Novocastra, Newcastle, UK; Abcam, Cambridge, MA 
and Cambridge, UK), showed improved results in combina-
tion with a range of superior detection systems (reviewed in 
ref. 6). IHC has several advantages; it is more widely available, 
relatively quick and cheap, preserves superior tumor morphol-
ogy on microscopic examination, and may be assessed on 
small number of tumor cells. However, approximately 20 pub-
lished studies describe a range of methodological approaches 
for antigen unmasking, slide preparation, primary antibody, 
secondary and amplification stages, not to mention different 
scoring systems, and definitions of a “positive case.”
What does a positive IHC test mean in this debate? 
Bearing in mind that the current, defining biomarker, at 
least under FDA rules, is a positive ALK FISH test, the 
key issue is the ability of a positive IHC test to predict the 
presence of ALK rearrangement as demonstrated by FISH. 
 High-sensitivity detection methods with either 5A4 or D5F3 
have demonstrated sensitivity and specificity of ALK IHC, for 
ALK fusion, of 90% to 100%.6 But still, the heterogeneity of 
test approaches and a lack of consensus of what constitutes a 
positive, predictive (for ALK fusion) IHC test remain a prob-
lem. There are no clinical trials directly validating a positive 
IHC test as a predictor of response to an ALK TKI, and the 
FDA has yet to “approve” any particular ALK IHC method 
for clinical use. The matter was made more complex when 
the European Medicines Agency approved crizotinib for use, 
underpinned by “a validated ALK test” without being more 
specific. Theoretically at least, ALK IHC can be used in 
Europe to select patients for crizotinib therapy.
In this month’s Journal of Thoracic Oncology, Wynes 
et al.9 present an international, interobserver study on the use 
of the D5F3 antibody and OptiView detection and amplifica-
tion system (D5F3-OptiView; Roche-Ventana, Tucson, AZ) in 
a cohort of 100 adenocarcinomas, 45 of which were positive 
and 55 negative on ALK FISH testing. There was an excellent 
interobserver agreement on IHC scoring, and sensitivity and 
specificity versus ALK FISH positivity were 90% and 95%, 
respectively. This study maintained excellent performance 
characteristics, despite samples being sourced from several 
centers, involving differences in preanalytical variables, and 
multiple observers. Other reports using the D5F3-OptiView 
combination, with cases from multiple sources but fewer slide 
readers,10,11 report even better figures, effectively 100% each. 
This staining and scoring methodology can also be consistently 
performed across multiple centers.12 The published database,6 
including a multicenter ring study,13 on the 5A4 antibody also 
suggests a robust technique, provided the necessary elements 
are used and rules are followed—this clone is not available 
as a diagnostic “kit.” This takes us some way toward a “real 
world” testing situation and should help give oncologists con-
fidence in IHC as a reliable ALK biomarker diagnostic. The 
author is unaware of any similar published studies of ALK 
FISH testing.
There are, of course, some issues with ALK IHC. Testing 
outcomes may be compromised by vagaries of preanalytical han-
dling, but so too for FISH testing. Some reports, many anecdotal, 
of discrepant ALK IHC or FISH tests (IHC+/FISH− or IHC−/
FISH+) probably reflect technical failures in one of the tests in 
many instances14 because of pre-cut section deterioration, fixa-
tion/processing/handling issues, lack of tumor in test sections, 
slide misinterpretation, clerical error, and so on. Nonetheless, 
true biological discrepancies may occur: A rearrangement may 
be present but may not be transcribed or translated; such cases 
may be associated with other driver mutations.15 Alk protein may 
be elevated in cases which lack gene rearrangement. This may 
be associated with ALK gene amplification.16
Interpretation of IHC is an important factor. The detec-
tion systems often used with the 5A4 clone deliver variable 
staining intensity, allowing for the traditional four-tier (0, 
1+, 2+, and 3+) scoring system. There is variability in the 
reported significance of a 1+ and even a 2+ stain, but 0 and 
3+ scores have a very high negative and positive predictive 
value, respectively, for FISH positivity. Thus, the definition 
of a positive predictive 5A4-based IHC test has been elusive 
and accounts for some of the “poor performance” reported 
for some test approaches. The detection and amplification sys-
tem used by Wynes et al.9 and others10–12 uses  tyramide-based 
chemistry that generates a relatively large amount of chromo-
gen (color stain on the tissue section) per molecule of bound 
D5F3 antibody.17 This shifts the dynamic range of the stain-
ing result, away from a graduated range of staining intensity 
to a more binary, on/off situation. This principle has been 
well discussed elsewhere.18 Wynes et al.,9 in line with others’ 
experience,6 however, indicate that the OptiView methodol-
ogy does not give a completely binary “present or absent” 
signal, but it is close to being so. Some cases undoubtedly 
show variable staining intensity, but H-scores do tend toward 
the extremes of the 0 to 300 range.17 Some cases show back-
ground staining that could lead to a false-positive call. In the 
author’s experience, such “borderline” cases are more likely 
to be either cytology cell block cases or cases from outside 
centers but have never been ALK FISH positive. This test 
may show staining in alveolar macrophages, bronchial gland 
cells, neural tissue, and occasional lymphoid cells. These are 
of crucial importance when interpreting difficult samples with 
few tumor cells admixed with non-neoplastic pulmonary tis-
sue. The IHC appearances of the D5F3-OptiView technique 
are different from other detection systems, and training on 
scoring helps interobserver agreement.12 This technique, with 
careful observation of what constitutes a “positive,” supported 
by these latest data presented here, seems to offer a reliable, 
standardized ALK IHC test.
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Given that IHC can be a reliable ALK testing strat-
egy, how should it be used? Although there are case reports 
of ALK IHC-positive, FISH-negative patients responding to 
crizotinib,19,20 there are no phase 3 clinical trials supporting 
ALK IHC as a primary, therapy-selecting biomarker. However, 
given that the overall response rate of cohorts selected by FISH 
is 53% to 65%, and that 17.5% of FISH-positive patients in 
one trial showed no disease control at all,3 it would be very 
surprising, given the close correlation between ALK IHC and 
FISH test outcomes, if ALK IHC positivity were not associ-
ated with similar clinical responses. The strong correlation 
between IHC and FISH negativity, and the pros and cons of 
IHC and FISH already mentioned above have underpinned the 
use of ALK IHC as a screening tool to eliminate many candi-
date cases from FISH testing where ALK IHC is negative. This 
approach is supported by the published data and the College 
of American Pathologists/International Association for the 
Study of Lung Cancer/Association for Molecular Pathology 
guidelines. Although there may be debate as to whether 1+ 
IHC-positive cases from sensitive 5A4-based studies should 
be FISH tested or not, IHC screening is still beneficial. With 
the D5F3-OptiView technique, the borderline cases would 
seem to be fewer, and anecdotal evidence suggests that they 
will not be ALK rearranged, but more data will be welcome.
Assuming analytical problems are solved, the tech-
nology becomes widely available, and requirements on 
quality and quantity of extracted DNA can be met21,22; will 
 next-generation sequencing technology make the ALK IHC/
FISH debate irrelevant? A reliable method to detect ALK gene 
rearrangements in DNA as part of a multiplex genomic screen 
would be very welcome. These findings would, however, still 
require validation in trials, as a method to detect patients likely 
to respond to ALK TKIs. As already mentioned, it is the abnor-
mally expressed protein, not the abnormal DNA sequence, 
which exerts oncogenic effects, and the protein is the target 
of the drug. There are suggestions and anecdotal reports that 
patients with ALK rearrangement (FISH or RT-PCR positive) 
but no protein expression (IHC negative) do not respond so 
well to ALK TKIs (personal communication, Yasushi Yatabe, 
MD, Aichi Cancer Centre, Nagoya, Japan).23 This may be part 
of the reason why, in the published trials, the response rates for 
ALK FISH-positive cohorts are “only” 53% to 65%. We face 
the intriguing possibility of the IHC test becoming the pri-
mary biomarker for ALK TKIs, perhaps with next-generation 
sequencing being used as the screening step.
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